Close

Anti-CEA (MFE23) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-MZ107)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CEA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CEA. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-CEA antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Advanced CEA+ malignancy.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CEA
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Advanced CEA+ malignancy
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Retroviral
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • MFE23
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CEA
  • Synonyms
  • CEA; CD66e;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data ELISA

Fig.1 Immunoreactivity of purified MFE-23::CPG2 confirmed by ELISA: CEA reactive MFE-23::CPG2 detected with anti-CPG2 before (open circle) and after (closed circle) 125I-radiolabeling.

CAR Construction : Latest CAR Construction

Fig.1 Immunoreactivity of purified MFE-23::CPG2 confirmed by ELISA: CEA reactive MFE-23::CPG2 detected with anti-CPG2 before (open circle) and after (closed circle) 125I-radiolabeling.

No signal was obtained when CEA-coated wells were probed with anti-CPG2 after incubating with a mixture of (unfused) MFE-23 and
CPG2 (open triangle).

Bhatia, J., Sharma, S. K., Chester, K. A., Pedley, R. B., Boden, R. W., Read, D. A., ... & Begent, R. H. (2000). Catalytic activity of an in vivo tumor targeted anti‐CEA scFv:: carboxypeptidase G2 fusion protein. International journal of cancer, 85(4), 571-577.

CAR scFv data FCM

Fig.2 Flow cytometric analysis of binding of secreted two-chain αCD3xαCEA diabodies to the surface of HeLa cell.

CAR Construction : Latest CAR Construction

Fig.2 Flow cytometric analysis of binding of secreted two-chain αCD3xαCEA diabodies to the surface of HeLa cell.

The numbers in the right corners of each histogram indicate the mean fluorescence intensity (MFI).

Mølgaard, K., Compte, M., Nuñez-Prado, N., Harwood, S. L., Sanz, L., & Alvarez-Vallina, L. (2017). Balanced secretion of anti-CEA× anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity. Gene Therapy, 24(4), 208-214.

CAR scFv data ELISA

Fig.3 CEA ELISA of the CPGz::MFE-23 SCFV fusion protein.

CAR Construction : Latest CAR Construction

Fig.3 CEA ELISA of the CPGz::MFE-23 SCFV fusion protein.

Negative controls: chemically coupled SBlO anti-hCG F(ab')2-CPG2 and E. co/i TGI cell extract carrying pMTL20. L, denotes (Gly,Ser), linker.

Michael, N. P., Chester, K. A., Melton, R. G., Robson, L., Nicholas, W., Boden, J. A., ... & Minton, N. P. (1996). In vitro and in vivo characterisation of a recombinant carboxypeptidase G2:: anti-CEA scFv fusion protein. Immunotechnology, 2(1), 47-57.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CEA (MFE23) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-MZ107). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.